Comparison of Accidents and Their Circumstances With Oral Anticoagulants
Launched by CNGE IRMG ASSOCIATION · Mar 2, 2015
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
The method includes the use of a national prospective observational cohort, involving 444 general practitioners From april to december 2014, health data of any adult patient consulting a general practitioner and receiving an oral anticoagulant treatment has been entered in a database. Each patient received an information for agreement to participate to the study (agreement for stastical analysis of their health data during one year follow up).
In March 2015, half of those patients will be chosen (stratification), using a matched stratification process, and will be followed up over one year...
Gender
ALL
Eligibility criteria
- Inclusion Criteria :
- • Patient consulting a GP
- • Patient Whatever the reason for consultation
- • Aged \>18 years
- • Receiving oral anticoagulant treatment by NOAC (apixaban, dabigatran or rivaroxaban) or VKA (acenocoumarol, fluindione, or warfarin)
- • Whatever the indication (prevention or treatment).
- • Having the following indications for anticoagulant treatment : non-valvular atrial fibrillation, prevention of DVT / PE (excluding orthopedic post-surgery) treatment DVT / PE
- Exclusion Criteria :
- • Aged \<18 years
- • Receiving concomitant injectable anticoagulant treatment (including relay phase)
- • Follow up impossible.
About Cnge Irmg Association
The CNGE IRMG Association is a dedicated clinical trial sponsor focused on advancing medical research and innovation in the field of genetic and rare diseases. Committed to improving patient outcomes, the association collaborates with leading healthcare professionals, researchers, and institutions to design and implement robust clinical trials that adhere to the highest ethical and regulatory standards. By fostering partnerships and leveraging cutting-edge technologies, CNGE IRMG Association aims to accelerate the development of novel therapies and enhance the understanding of complex medical conditions, ultimately contributing to the well-being of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Albens, , France
Bordeaux, , France
Chablis, , France
Dessenheim, , France
Dijon, , France
Flumet, , France
Gemenos, , France
Grenay, , France
Guesnain, , France
Hatten, , France
Hinx, , France
La Madeleine, , France
Les Marches, , France
Limoges, , France
Mulsanne, , France
Outreau, , France
Paris, , France
Rupt Sur Moselle, , France
Saint Jean D'arvey, , France
Saint Amant Tallende, , France
Saint Etienne, , France
Saint Jean De Braye, , France
Saultain, , France
Sellieres, , France
Seraincourt, , France
Soisy Sous Montmorency, , France
St Georges D'orques, , France
Strasbourg, , France
Tournus, , France
Tours, , France
Villeurbanne, , France
Vitry Sur Seine, , France
Vourey, , France
Patients applied
Trial Officials
Joël COGNEAU, MD
Principal Investigator
IRMG
Paul FRAPPE, MD
Study Director
University of Saint-Etienne
Jean-Pierre JACQUET, MD
Study Director
University of Grenoble
Jean-Luc BOSSON, MD PhD
Study Director
University of Grenoble
François Lacoin, MD
Study Director
IRMG
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials